Citi Pharma Limited (CPHL): Result Review: CPHL 3QFY25 EPS Re0.96 - By Sherman Research

<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Citi Pharma Limited (CPHL) announced 3QFY25 result today where in company posted earnings of Rs220mn (EPS Re0.96) as compared to net earnings of Rs211 (EPS Re0.93) during the same period last year, up by 4%YoY. The earning slightly grew mainly due to expansion in gross margins and lower effective taxation.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">During 3QFY25, the company&rsquo;s topline declined by 6%YoY to Rs3.3bn, primarily due to depressed international API prices, which are linked to falling crude oil prices. Additionally, lower volumetric sales in the pharma sector further contributed to the decline.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-s...